The new global pharma order India could lead

Summary: A sweeping US law is forcing drugmakers to cut China-linked suppliers. And India is next in line. Our analysis explains the Biosecure Act, the global reshuffle it triggers, and the Indian companies best placed to capture the flow of contracts. After years of leaning on China for critical drug ingredients, the US is redrawing its supply map, and India is next in line to build it. A sweeping new bill, the Biosecure Act, seeks to restrict US government-backed research and drug manufacturing from using equipment, software or outsourced services from companies tied to nations deemed risky for national security – chief among them, China. Though Chinese firms will primarily be the most impacted, the bill allows the US to dynamically decide on ‘companies of concern’ and bar them from supplying to state-backed institutions and drugmakers. In practice, this affects everything, from lab equipment like gene sequencers to contract research, drug manufacturing and digital lab systems in biotech. For Indian companies, this is an opportunity. As US sponsors – companies developing drugs – seek trusted partners outside China, firms with global compliance standards, strong capacity and cost efficiency like those in India automatically become attractive. How the new rules will work Here’s what the new rule does in plain terms. US drug developers and research institutions that rely on government support can no longer work with companies the law flags as ‘of concern’. That includes any company supplying lab equipment, manufacturing drugs or performing outsourced research. Many US sponsors hire outside firms to do parts of their work. Contract research organisations (CROs) handle lab experiments and testing. Contract development and manufacturing organisations (CDMOs) or contract manufacturing